Breckenridge Pharmaceutical Enters Agreement with Oman Pharmaceutical Products Company LLC
BOCA RATON, Fla., April 4, 2011 /PRNewswire/ — Breckenridge is announcing that it entered into an agreement with Oman Pharmaceutical Products Company LLC, of Salalah, Sultanate of Oman to market Neomycin Sulfate Tablets. Under the terms of the agreement, the product will be manufactured by Oman Pharma, and marketed and distributed by Breckenridge on an exclusive basis in the United States. The ANDA has been approved by the U.S. Food and Drug Administration (FDA), and the companies began shipping the product at the start of 2011.
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders.
Oman Pharmaceutical Products Co. L.L.C. (OPP) is a Global Pharmaceutical company specializing in the development, production & marketing of generic and OTC pharmaceuticals in the GCC and world-wide. The ultramodern plant of Oman Pharmaceutical Products Co. LLC is located in Salalah, South of Oman. The manufacturing plants are approved by U.S. Food and Drug Administration (FDA), UK MHRA, Australian TGA, German Authorities and the GCC health authorities and are regularly inspected by these Health Authorities. www.omanpharma.com